TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited announced promising results from its EFTISARC-NEO Phase II trial, which were presented at the CTOS 2025 Annual Meeting. The trial demonstrated significant tumor hyalinization/fibrosis in patients with soft tissue sarcoma (STS) using a novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA. This combination showed a strong immune response, potentially leading to better patient outcomes and survival rates. The findings suggest that efti could be beneficial in treating early-stage cancers, expanding its role in the cancer treatment landscape.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited is a late-stage immunotherapy company focused on targeting cancer and autoimmune diseases. The company is involved in developing treatments that activate the immune system to fight these conditions.
Average Trading Volume: 2,426,896
Technical Sentiment Signal: Sell
Current Market Cap: A$375.3M
Learn more about IMM stock on TipRanks’ Stock Analysis page.